 Our study suggests that combining DMKG with radioimmunotherapy may be an effective strategy for treating triple negative breast cancer, TNBC. The combination therapy can induce apoptosis in tumor cells, increase the release of antigens and inflammatory factors, reduce autophagy, and promote infiltration of CD8 plus T cells into the tumor area. Additionally, it can reduce the proportion of regulatory T cells and increase the expression of PD-L1 at immune checkpoints, leading to improved efficacy of the treatment. This article was authored by Hong Pey Tan, Jiahao Liu, Jing Huang, and others.